Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA5 | O75582 | 8/20 | 0.46 |
| ▸ | ROCK1 | Q13464 | 6/20 | 0.32 |
| ▸ | AKT1 | P31749 | 6/20 | 0.32 |
| ▸ | AKT2 | P31751 | 6/20 | 0.32 |
| ▸ | AKT3 | Q9Y243 | 6/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.31 |
| ▸ | GSK3A | P49840 | 2/20 | 0.31 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.31 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | PRKACA | P17612 | 1/20 | 0.31 |
| ▸ | MARK3 | P27448 | 1/20 | 0.31 |
| ▸ | GRK5 | P34947 | 1/20 | 0.31 |
| ▸ | CDK8 | P49336 | 1/20 | 0.31 |
| ▸ | CLK2 | P49760 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | CDK7 | P50613 | 1/20 | 0.31 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.31 |
| ▸ | PRKX | P51817 | 1/20 | 0.31 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17437583 | 0.70 | RPS6KA5 (0.55) | RPS6KA5ROCK1AKT1AKT2AKT3 | |
| SCHEMBL27191772 | 0.69 | RPS6KA5 (0.57) | RPS6KA5ROCK1DYRK1ACDK2RPS6KA1 | |
| SCHEMBL4720745 | 0.63 | RPS6KA5 (1.00) | RPS6KA5ROCK1AKT1AKT2AKT3 | |
| SCHEMBL14050028 | 0.63 | RPS6KA5 (0.77) | RPS6KA5ROCK1AKT1AKT2AKT3 | |
| SCHEMBL27192343 | 0.58 | PARP1 (0.36) | RPS6KA5LRRK2 | |
| SCHEMBL16054218 | 0.57 | RPS6KA5 (0.41) | RPS6KA5 | |
| SCHEMBL27191997 | 0.56 | TLR7 (0.39) | RPS6KA5 | |
| SCHEMBL17437447 | 0.56 | RPS6KA5 (0.38) | RPS6KA5 | |
| SCHEMBL17437421 | 0.55 | ALDH1A1 (0.42) | RPS6KA5 | |
| SCHEMBL15057859 | 0.55 | RPS6KA5 (0.42) | RPS6KA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1653961-A4 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORP (US) | 2009-04-01 | — | — | EP | disclosed |
| US-20080255143-A1 | Inhibitors of Akt Activity | SMITHKLINE BEECHAM CORPORATION (PA) | 2008-10-16 | — | — | US | disclosed |
| US-20070161665-A1 | Cancer treatment method | SMITHKLINE BEECHAM CORPORATION | 2007-07-12 | — | — | US | disclosed |
| EP-1682123-A1 | CANCER TREATMENT METHOD | SmithKline Beecham (Cork) Limited (IE) | 2006-07-26 | — | — | EP | disclosed |
| EP-1653961-A1 | INHIBITORS OF AKT ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2006-05-10 | — | — | EP | disclosed |
| WO-2005046678-A1 | CANCER TREATMENT METHOD | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2005-05-26 | — | — | WO | disclosed |
| WO-2005011700-A1 | INHIBITORS OF Akt ACTIVITY | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255143-A1 | Inhibitors of Akt Activity | PI4KB, PIK3CA, AKT2 | RPS6KA5 156/4885ROCK1 478/4885AKT1 5/4885 |
| US-20070161665-A1 | Cancer treatment method | ERBB2, EGFR, PIK3CA | RPS6KA5 82/4885ROCK1 1167/4885AKT1 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.